Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 21, 2016; 22(27): 6287-6295
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6287
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6287
Table 3 Vascular endothelial growth factor and angiopoietin-2 in colon cancer patients treated with FOLFOX regimen
| VEGF (pg/mL) | Ang-2 (pg/mL) | |||
| Total | After immunodepletion | Total | After immunodepletion | |
| Patient No. 1 | 200.24 | 205.62 | 242.10 | 270.48 |
| Patient No. 2 | 126.25 | 140.36 | 307.18 | 312.01 |
| Patient No. 3 | 188.75 | 182.50 | 662.65 | 733.45 |
| Patient No. 4 | 255.15 | 232.34 | 388.20 | 477.20 |
- Citation: Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295
- URL: https://www.wjgnet.com/1007-9327/full/v22/i27/6287.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i27.6287